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Major advances in understanding the pathogenesis of inherited metabolic disease caused by mitochondrial DNA mutations have
yet to translate into treatments of proven efﬁcacy. Leber’s hereditary optic neuropathy is the most common mitochondrial DNA
disorder causing irreversible blindness in young adult life. Anecdotal reports support the use of idebenone in Leber’s hereditary
optic neuropathy, but this has not been evaluated in a randomized controlled trial. We conducted a 24-week multi-centre
double-blind, randomized, placebo-controlled trial in 85 patients with Leber’s hereditary optic neuropathy due to
m.3460G4A, m.11778G4A, and m.14484T4C or mitochondrial DNA mutations. The active drug was idebenone 900 mg/
day. The primary end-point was the best recovery in visual acuity. The main secondary end-point was the change in best visual
acuity. Other secondary end-points were changes in visual acuity of the best eye at baseline and changes in visual acuity for
both eyes in each patient. Colour-contrast sensitivity and retinal nerve ﬁbre layer thickness were measured in subgroups.
Idebenone was safe and well tolerated. The primary end-point did not reach statistical signiﬁcance in the intention to treat
population. However, post hoc interaction analysis showed a different response to idebenone in patients with discordant visual
acuities at baseline; in these patients, all secondary end-points were signiﬁcantly different between the idebenone and placebo
groups. This ﬁrst randomized controlled trial in the mitochondrial disorder, Leber’s hereditary optic neuropathy, provides
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well tolerated.
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Introduction
Inherited disorders of mitochondrial energy metabolism are a
major cause of metabolic disease affecting more than 1/5000 of
the population (Schaefer et al., 2004). Despite major advances in
understanding the molecular basis of these disorders, treatment
options are extremely limited.
Leber’s hereditary optic neuropathy (LHON; MIM 535000) is
the most common mitochondrial disorder affecting more than
1:14 000 males (Man et al., 2003). It causes progressive irrevers-
ible blindness and has a dramatic impact on quality of life
(Kirkman et al., 2009). Over 90% of European and North
American patients harbour one of three pathogenic mutations
of mitochondrial DNA (m.3460G4A, m.11778G4A, and
m.14484T4C), which affect complex I (Nicotinamide adenine
dinucleotide–ubiquinone oxidoreductase) of the mitochondrial
respiratory chain (Harding et al., 1995). These mutations lead
to a defect of ATP (adenosine triphosphate) synthesis accompa-
nied by increased production of oxygen-free radicals causing ret-
inal ganglion cell dysfunction and loss (Baracca et al., 2005;
Zanna et al., 2005). Although it can affect both genders at
any age, LHON is typically prevalent among young adult males
(median onset at 24 years) (Nikoskelainen et al., 1996). In the
acute phase, patients describe a loss of colour vision in one
eye followed by a painless subacute decrease in central visual
acuity accompanied by an enlarging centrocaecal scotoma. The
second eye usually follows a similar course within 3 months, and
signiﬁcant improvements in visual acuity are rare for
m.11778A4G and m.3460A4G patients. In the chronic phase,
patients usually have a bilateral visual deﬁcit that is symmetrical
and life-long. Most remain legally blind, are unable to drive
a motor vehicle, and are unable to ﬁnd employment
(Newman et al., 1991; Riordan-Eva et al., 1995; Nikoskelainen
et al., 1996).
Anecdotally, patients with LHON have reported improve-
ments in vision following treatment with the short-chain synth-
etic benzoquinone idebenone [2,3-dimethoxy-5-methyl-6-(10-
hydroxydecyl)-1,4-benzoquinone] (Mashima et al., 1992; Carelli
et al., 1998). Idebenone is a potent antioxidant and inhibitor of
lipid peroxidation, interacting with the mitochondrial electron
transport chain and facilitating mitochondrial electron ﬂux in by-
passing complex I (Haefeli et al., 2011). However, therapeutic
effects of idebenone in patients with LHON have only been re-
ported in isolated case reports and in a small retrospective
open-labelled study (Mashima et al., 1992; Cortelli et al., 1997;
Carelli et al., 1998, 2001; Mashima et al., 2000; Barnils et al.,
2007).
Materials and methods
Study design and patients
Eighty-ﬁve patients enrolled in a prospective, randomized, double-blind,
placebo-controlled study (Rescue of Hereditary Optic Disease Outpatient
Study, RHODOS; ClinicalTrials.gov identiﬁer: NCT00747487) in Munich,
Germany (n=44); Newcastle upon Tyne, England (n=30); and
Montreal, Canada (n=11). Inclusion criteria were met if patients were
between 14 and 64 years of age, harboured m.3460G>A,
m.11778G>A, or m.14484T>C mitochondrial DNA mutations, described
vision loss due to LHON within 5 years, did not take drugs of abuse, and
were neither pregnant nor breastfeeding. The study had ethical and
institutional review board approval. All patients gave written informed
consent. The trial proﬁle is summarized in Supplementary Fig. 1.
Randomization and masking
Patients were randomly assigned following a centralized randomiza-
tion procedure to receive idebenone (Catena 150mg, Santhera
Pharmaceuticals) 900mg/day (300mg three times a day during meals)
or placebo for 24 weeks in a 2:1 ratio. This dose was chosen because
it had previously been shown to be well tolerated. Patients were stra-
tiﬁed by disease history and mitochondrial DNA mutation. A
computer-generated randomization list was created for each stratum
(Clintrak) with blocks (block size: 6) containing idebenone and placebo
allocations in the correct proportion but random order. Each patient
was assigned the next available treatment for the appropriate stratum
by an independent provider (BIOP). The study site was informed of
the medication kit number to be dispensed to the patient, ensuring
that the blinding was maintained. Details of the randomization pro-
cedure were deﬁned in a Study Medication Assignment Guideline.
Compliance was monitored by pill count and idebenone serum levels.
Treatment outcomes
The main clinical efﬁcacy analyses related to visual acuity are shown in
Fig. 1A. The primary end-point was the best recovery of visual acuity
between baseline and Week 24 determined with an Early Treatment
Diabetic Retinopathy Study chart (van den Bosch and Wall, 1997). In
patients with neither eye improving in visual acuity between baseline
and Week 24, the change in visual acuity representing the least wor-
sening was evaluated as best recovery. Patients only able to count
ﬁngers, detect hand motion or light perception were assigned
logMAR values 2.0, 2.3 and 2.6, respectively (Lange et al., 2009).
Change from baseline to Week 24 in best visual acuity was the pre-
speciﬁed main secondary end-point. Other secondary end-points were
the change in visual acuity of the best eye at baseline, and change in
visual acuity for both eyes in each patient. Valid visual acuity data
were available for 82 patients in the intent-to-treat population.
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eyes that changed logMAR50.2 (corresponding to 510 Early
Treatment Diabetic Retinopathy Study chart letters). Retinal nerve ﬁbre
layer thickness was assessed in 41 patients by optical coherence tomog-
raphy (Barboni et al., 2005; Subei and Eggenberger, 2009). Thirty-nine
patients in Munich were also assessed for colour contrast sensitivity by
determining red–green (Protan) and blue–yellow (Tritan) colour confu-
sion using computer graphics techniques (Arden and Wolf, 2004). All
patients were assessed for Clinical Global Impression of Change (GCIC)
determined on a 7-point scale from marked improvement (1) to marked
deterioration (7) with no change representing a score of 4 (Guy, 1976).
Statistical analyses
Power calculations indicated that 84 patients would provide 80% stat-
istical power to detect a difference of 0.2 (SD 0.3) logMAR between
idebenone and placebo. Data were analysed using the mixed-model
repeated measures method (Verbeke and Molenberghs, 2000).
Treatment assignment, visit and interaction between the treatment
assignment and visit, and pre-speciﬁed stratiﬁcation factors (disease
history and mitochondrial DNA mutation) were included as ﬁxed fac-
tors, with baseline assessment as a covariate and subject as a random
factor. The inﬂuence of additional factors (e.g. discordant visual acuities
at baseline) was investigated by including the factor and interaction
between the factor and treatment assignment to the mixed-model re-
peated measures model. The interaction terms were tested on a
two-sided signiﬁcance level of 0.10; otherwise a two-sided signiﬁcance
level of 0.05 was used. Authors had full and unrestricted access to the
data and all co-authors contributed to the interpretation of the study.
Results
Baseline clinical data
The age, gender and mutation distribution were typical for
Caucasian patients with LHON and were balanced between
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Figure 1 (A) Visual acuity efﬁcacy end-points (ﬁlled arrows) between baseline and Week 24. (1) Primary end-point—best recovery/least
worsening in visual acuity, one value per patient. (2) Main secondary end-point—change in best visual acuity, one value per patient. (3)
Pre-speciﬁed secondary end-point—change in visual acuity of best eye at baseline, one value per patient. (4) Pre-speciﬁed secondary
end-point—change in visual acuity of all eyes (both eyes of a patient considered independent), two values per patient. (B) Visual acuity at
baseline for all patients. Both eyes are shown for each subject, connected by a solid line (grey squares = eye with better visual acuity; black
squares = eye with worse visual acuity). BL = baseline; CF = ﬁnger counting; HM = hand motion; LP = light perception; VA = visual acuity.
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for 41 year, 85% had a logMAR51.0 in both eyes (correspond-
ing to legal blindness in many countries); and 37% had interocular
acuity discordance of logMAR 40.2 (Fig. 1B).
Safety and tolerability
All 85 patients were evaluated for safety and tolerability.
Compliance with study medication intake was high (mean pill
count compliance of 96.5%, SD 6.8%). Seven patients premature-
ly discontinued treatment (n = 4 of 30 on placebo; n = 3 of 55 on
idebenone), one discontinuation in each treatment group was
related to adverse events. The nature, severity and frequency of
the adverse events observed were indistinguishable between the
study groups. Two serious adverse events were reported: a case of
infected epidermal cyst (idebenone group) and one case of epi-
staxis (placebo group); both not considered to be due to the study
medication. No clinically signiﬁcant changes of vital signs and
other biochemical or haematological parameters were observed.
Visual acuity
For the primary end-point (best recovery of visual acuity), the
placebo group changed by logMAR 0.071 [95% conﬁdence
interval (95% CI): 0.176 to 0.034), while the idebenone group
changed by logMAR 0.135 (95% CI: 0.216 to 0.054); the
difference between groups did not reach statistical signiﬁcance
at 24 weeks (logMAR 0.064; 95% CI: 0.184 to 0.055;
P=0.291) (Fig. 2A). However, a trend towards improvement
with idebenone was observed for the secondary end-points of
change in best visual acuity (Idebenone: change in logMAR:
0.035; 95% CI: 0.126 to 0.055; Placebo: logMAR +0.085;
95% CI: 0.032 to 0.203; difference between groups: logMAR
0.120; 95% CI: 0.255, 0.014; P=0.078) and the change in
visual acuity of the best eye (Idebenone: change in logMAR:
0.030; 95% CI: 0.120 to 0.060; Placebo: logMAR +0.098;
95% CI: 0.020 to 0.215; difference between groups: logMAR
0.128; 95% CI: 0.262 to 0.006; P=0.061) for the intent-
to-treat population (Fig. 2C and E). When data from all eyes
were combined, another pre-speciﬁed secondary end-point,
there was a signiﬁcant difference in the mean visual acuity be-
tween the idebenone and placebo group at 24 weeks (Idebenone:
change in logMAR: 0.054; 95% CI: 0.114 to 0.005; Placebo:
logMAR +0.046; 95% CI: 0.032 to 0.123; Difference between
groups: logMAR 0.100; 95% CI: 0.188 to 0.012; P=0.026;
Fig. 2G). Excluding patients with the m.14484T4C mutation,
which is known for its spontaneous recovery rate in visual acuity,
led to a larger difference in the change of visual acuity between
idebenone- and placebo-treated patients. Speciﬁcally, for the com-
bined patients carrying m.11778G4A and m.3460G4A
Table 1 Patient demographics
Idebenone 900mg/day
(n=55)
a
Placebo (n=30)
a Total (n=85)
a
Age, mean  SD; [median] (range) (years) 33.8  14.8;
[30.0] (14–63)
33.6  14.6;
[28.5] (14–66)
33.7  14.6;
[30.0] (14–66)
Sex
Male, n (%) 47 (85.5) 26 (86.7) 73 (85.9)
Female, n (%) 8 (14.5) 4 (13.3) 12 (14.1)
Mutations, n (%)
m.11778 G4A 37 (67.3) 20 (66.7) 57 (67.1)
m. 14484 T4C 11 (20) 6 (20) 17 (20.0)
m. 3460 G4A 7 (12.7) 4 (13.3) 11 (12.9)
BMI, mean  SD; [median] (range) (kg/m
2) 24.2  4.4; [23.5]
(16.1–37.0)
24.9  4.4; [24.5]
(18.9–35.1)
24.5  4.4; [23.6]
(16.1–37.0)
Months since onset of vision loss,
mean  SD; [median] (range)
22.8  16.2;
[17.8] (3–62)
23.7  16.4;
[19.2] (2–57)
23.1  16.2;
[18.2] (2–62)
Patients with onset of symptoms 41 year, n (%) 36 (65.5) 19 (63.3) 55 (64.7)
Patients with logMAR51.0,
b
n (%) one eye/both eyes
5 (9.4)/45 (84.9) 2 (6.9)/25 (86.2) 7 (8.5)/70 (85.4)
Patients with logMAR 51.0 in both eyes,
b n (%) 3 (5.7) 2 (6.9) 5 (6.1)
Patients ‘off chart’,
c n (%) one eye/both eyes 11 (20.8)/25 (47.2) 3 (10.3)/13 (44.8) 14 (17.1)/38 (46.3)
Patients with discordant visual acuities,
d n (%) 20 (37.7) 10 (34.5) 30 (36.6)
LogMAR: mean  SD,
e (n)
Best eye 1.61  0.64 (53) 1.57  0.61 (29) 1.59  0.62 (82)
Worst eye 1.89  0.49 (53) 1.79  0.44 (29) 1.86  0.47 (82)
Both eyes 1.75  0.58 (106) 1.68  0.54 (58) 1.73  0.57 (164)
an=82 (n=53 for idebenone; n=29 for placebo) for all visual acuity data.
blogMAR51.0 in both eyes corresponds to legal blindness in most countries.
clogMAR41.68 (patients unable to read any letter on the chart).
ddeﬁned as patients with difference in logMAR40.2 between both eyes.
eapplying logMAR 2.0 for counting ﬁngers; logMAR 2.3 for hand motion; logMAR 2.6 for light perception.
BMI = body mass index.
2680 | Brain 2011: 134; 2677–2686 T. Klopstock et al.l
o
g
M
A
R
-0.2
-0.15
-0.1
-0.05
0
0.05
048 1 2 1 6 2 0 2 4 W
P=0.478 P=0.439 P=0.291
A
ITT population
b
e
s
t
r
e
c
o
v
e
r
y
B
-0.4
-0.3
-0.2
-0.1
0
0.1
048 1 2 1 6 2 0 2 4 W
P=0.707 P=0.118 P=0.011
Placebo
Idebenone
-0.1
-0.05
0
0.05
0.1
0.15
0.2
0 4 8 1 21 62 0 2 4 W
P=0.354 P=0.034 P=0.078
l
o
g
M
A
R
C
b
e
s
t
v
i
s
u
a
l
a
c
u
i
t
y
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
048 1 2 1 6 2 0 2 4 W
P=0.423 P=0.006 P=0.003
Subgroup of patients
with discordant VA at baseline
D
-0.2
-0.1
0
0.1
0.2
048 1 2 1 6 2 0 2 4 W
P=0.231 P=0.036 P=0.026
l
o
g
M
A
R
G
v
i
s
u
a
l
a
c
u
i
t
y
i
n
a
l
l
e
y
e
s
H
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0 4 8 12 16 20 24 W
P=0.500 P=0.005 P=0.0001
-0.1
-0.05
0
0.05
0.1
0.15
0.2
048 1 2 1 6 2 0 2 4 W
P=0.250 P=0.020 P=0.061
l
o
g
M
A
R
c
h
a
n
g
e
i
n
v
i
s
u
a
l
a
c
u
i
t
y
o
f
t
h
e
b
e
s
t
e
y
e
E
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
048 1 2 1 6 2 0 2 4 W
P=0.424 P=0.003 P=0.003
F
Figure 2 Change in visual acuity (logMAR) end-points over time for the change in best recovery of visual acuity (A and B), change in best
visual acuity (C and D), change in visual acuity of the patients’ best eye at baseline (E and F) and change in visual acuity for all eyes (G and
H). For each analysis two populations are presented: the whole study population (n = 82, intent-to-treat population for visual acuity
end-points) (A, C, E and G) and subpopulation of patients with discordant visual acuities at baseline (n = 30, B, D, F and H). Filled squares/
solid line = idebenone group; ﬁlled circles/dashed lines = placebo group, P-values for comparison between idebenone and placebo groups.
Data are estimated means (SEM) from mixed model for repeat measures based on the change from baseline. ITT = intent-to-treat;
VA = visual acuity; W = weeks.
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primary end-point reached logMAR 0.092 (95% CI: 0.229 to
0.045; P=0.187) and for the main secondary end-point, the
change in best visual acuity, the point estimate was logMAR
0.169 (95% CI: 0.326 to 0.011; P=0.037). All of the
observed changes in visual acuity in the intent-to-treat population
correlated with the patients’ clinical global impression of change
(for best recovery in visual acuity: R=0.32, P=0.005; for
change in best visual acuity: R = 0.34, P=0.002; for change
in visual acuity of the patient’s best eye: R=0.33, P=0.004
and for the change in visual acuity for all eyes: R=0.32,
P50.001).
Given the observed trend, we performed a post hoc subanalysis
of the patients with discordant visual acuities at baseline (i.e. pa-
tients with difference of logMAR 40.2 between eyes, Fig. 1A),
based on the premise that this objectively deﬁned group (n = 30)
would include patients at the highest risk of further visual loss. A
formal test of the interaction between the effect of idebenone and
discordance of visual acuity at baseline was signiﬁcant for all sec-
ondary end-points, indicating that the difference between idebe-
none and placebo groups was different among patients with
discordant visual acuities versus patients with concordant visual
acuity. The estimated mean difference among the patients with
discordant visual acuities in best recovery in visual acuity between
the idebenone and placebo group was logMAR = 0.285; 95%
CI: 0.502 to 0.068; P=0.011 (Fig. 2B) with similar results for
the best visual acuity (difference between groups: logMAR =
0.421; 95% CI: 0.692 to 0.150; P=0.003; Fig. 2D),
change in visual acuity of the patient’s best eye (difference be-
tween groups: logMAR = 0.415; 95% CI: 0.686 to 0.144;
P=0.003; Fig. 2F), and when data for all eyes was combined
(difference between groups: logMAR = 0.348; 95% CI:
0.519 to 0.176; P=0.0001; Fig. 2H). In contrast, among
the patients with concordant visual acuity, no signiﬁcant differ-
ences were seen in any of the end-points: estimated differ-
ence between the idebenone and placebo group being logMAR
+0.056 (95% CI: 0.091 to +0.202; P=0.452) for best recov-
ery in visual acuity; logMAR +0.037 (95% CI: 0.107 to
+0.180; P=0.613) for the best visual acuity; logMAR +0.022
(95% CI: 0.120 to +0.165; P=0.757) for change in visual
acuity of the patient’s best eye and logMAR +0.028 (95% CI:
0.070 to +0.125; P=0.577) when data for all eyes was
combined.
The trend towards improvement with idebenone was also ap-
parent in a responder analysis (Table 2). For patients with discord-
ant visual acuities at baseline, there was a 45% difference in the
responders for the best recovery of visual acuity (P=0.024); and a
32.5% difference in the end-point assessing the change in visual
acuity for all eyes (P=0.011). Of particular interest were the pa-
tients unable to read any letters on the chart at baseline (‘off-chart
patients’). When all eyes were considered independently, 20% of
the eyes of the patients receiving idebenone were able to read at
least one full line on the chart at Week 24, while none of the
patients in the placebo group showed this improvement
(P=0.008).
Colour contrast sensitivity
Most patients (92%) had abnormal colour contrast sensitivity at
baseline in both protan and tritan domains in both eyes. There
was a signiﬁcant improvement in the tritan colour contrast in the
idebenone group at 12 weeks (difference between groups:
14.51%; 95% CI: 24.19 to 4.83; P=0.004) and 24
weeks (difference between groups: 13.63%; 95% CI: 23.61
Table 2 Responder analyses for change in visual acuity
Population Analysis Idebenone (%) Placebo (%) P
a
Intent-to-treat population (n=82):
proportion of patients with change of
logMAR of 0.2 or more at Week 24
b
Improvement: best recovery in visual acuity 20/53 (37.7) 7/29 (24.1) 0.231
Improvement: best visual acuity 14/53 (26.4) 5/29 (17.2) 0.420
Improvement in visual acuity of all eyes
c 30/106 (28.3) 10/58 (17.2) 0.131
Worsening in visual acuity of all eyes
c 18/106 (17.0) 17/58 (29.3) 0.075
Subgroup of patients with discordant
visual acuities at baseline (n=30):
proportion of patients with change of
logMAR of 0.2 or more at Week 24
b
Improvement: best recovery in visual acuity 11/20 (55.0) 1/10 (10.0) 0.024
Improvement: best visual acuity 6/20 (30.0) 0/10 (0.0) 0.074
Improvement in visual acuity of all eyes
c 15/40 (37.5) 1/20 (5.0) 0.011
Worsening in visual acuity of all eyes
c 8/40 (20.0) 9/20 (45.0) 0.067
Intent-to-treat population: patients with
logMAR 40.5 in at least one eye at
baseline
Deteriorate to logMAR 1.0 or more 0/6 (0) 2/2 (100) 0.036
Subpopulation of patients who were off
chart at baseline with both eyes
Could read at least ﬁve letters on the chart
at Week 24 with at least one eye
7/25 (28.0) 0/13 (0.0) 0.072
Eyes that were off chart at baseline Could read at least ﬁve letters on the chart
at Week 24
12/61 (19.7) 0/29 (0.0) 0.008
aP-values calculated with Fisher’s exact test.
bPatients with premature discontinuation were classiﬁed as non-improvers.
cEyes considered independent.
2682 | Brain 2011: 134; 2677–2686 T. Klopstock et al.to 3.66; P=0.008) (Fig. 3). A similar trend was observed in the
protan domain, but this did not reach statistical signiﬁcance.
Retinal nerve ﬁbre layer thickness
There was no difference in the pattern of retinal nerve ﬁbre layer
thickness at baseline for patients grouped by disease onset of 46
months, 6 months to 1 year, and 41 year (Fig. 4A). Consistent
with the visual acuity data, there was a trend towards maintaining
retinal nerve ﬁbre layer thickness in the idebenone group in su-
perior, nasal and inferior quadrants, among patients with 46
months disease history (Fig. 4B). Due to the small sample size,
no formal statistical analysis was conducted.
Discussion
Considerable advances in our understanding of the molecular and
biochemical basis of mitochondrial DNA-associated diseases have
not yet translated into treatments of proven efﬁcacy. A major
hurdle has been the inherent difﬁculties of conducting
adequately-powered randomized placebo-controlled clinical trials
for such rare genetic diseases. Recruitment often presents a
major challenge, in part due to limited disease awareness among
general hospital and community physicians. In addition, the lack of
detailed natural history studies makes it difﬁcult to select clinically
meaningful trial end-points to inform a priori power calculations.
Finally, patients often ﬁnd the prospect of taking placebo un-
acceptable and self-medicate, using Internet-based suppliers of
vitamins, food supplements and unapproved medication. All of
these issues are relevant for LHON, limiting previous clinical inves-
tigations to underpowered, open-labelled studies (Mashima et al.,
2000; Newman et al., 2005). Employing recently established pa-
tient registries in Germany (mitoNET) and the UK (MRC cohort),
we were able to conduct the ﬁrst adequately-powered randomized
placebo-controlled trial for this disorder.
Although this study did not meet the primary end-point, all
pre-speciﬁed secondary visual acuity end-points, subgroup, and
responder analyses pointed towards a beneﬁcial effect for idebe-
none, particularly for patients with discordant visual acuities
between the two eyes. Although we chose best recovery in
visual acuity as the primary end-point, both change in best
visual acuity and change in visual acuity in both eyes are equally
justiﬁable end-points from a clinical perspective, and arguably the
change in best visual acuity is the most relevant to the patients’
needs—being the closest related to visual function in daily life.
Colour contrast sensitivity data provided an independent meas-
urement of the potential treatment effects of idebenone. In agree-
ment with previous studies (Grigsby et al., 1991; Ventura et al.,
2007), we observed a high incidence of defects affecting both the
red–green (protan) and blue–yellow (tritan) colour domains.
LHON preferentially affects the smallest diameter optic nerve
ﬁbres in the parvocellular bundle that mediate protan colour
vision (Grigsby et al., 1991; Ventura et al., 2007). The relative
resistance of the larger stratiﬁed ﬁbres mediating tritan vision
through the koniocellular pathway may explain why we only
observed an effect of idebenone in this domain. The natural his-
tory of retinal nerve ﬁbre layer thickness in LHON (Barboni et al.,
2005) reveals a complex biphasic pattern, where the value in-
creases during the acute phase (due to retinal nerve ﬁbre layer
swelling), followed by a decrease as the patient enters the chronic
phase (due to the resolution of retinal nerve ﬁbre layer swelling
and subsequent axonal loss). Subdividing patients into different
subgroups based on the disease duration to account for the com-
plex pattern in change of retinal nerve ﬁbre layer thickness mark-
edly reduced statistical power, explaining why the observed trend
did not reach signiﬁcance in patients 46 months since disease
onset.
Although subgroup analysis should be interpreted with great
caution, subdividing patients into those with and without discord-
ant interocular visual acuities indicated that patients with discord-
ant eyes had the largest treatment effect. It is notoriously difﬁcult
to subdivide patients with LHON into ‘acute’ and ‘chronic’ disease
phases based solely on their recollection of symptom onset, since
well-established cases can present only after the second eye be-
comes clinically involved (Riordan-Eva et al., 1995). In order to
avoid this problem, we used a more objective categorization of
patients into those with discordant and concordant visual acuities.
This was based on the published literature where, in general, a
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in late-stage patients (Newman et al., 1991; Riordan-Eva et al.,
1995), suggesting that asymmetric interocular visual acuities are
more likely to be found among patients with a relatively recent
onset of symptoms. However, in our study of patients with symp-
toms of 55 years duration, we saw no relationship between dis-
cordant visual acuities and the duration of reported symptoms. A
much longer study will be required to determine whether the fre-
quency of discordant visual acuities does correlate with disease
duration, as suggested by the literature (Newman et al., 1991;
Riordan-Eva et al., 1995), but this would not alter our main con-
clusions. Based on our ﬁndings, idebenone appeared to prevent
further visual loss in patients with discordant visual acuities, in
contrast, to the placebo group whose visual acuities continued
to deteriorate during the 24 week study period. The clinical sig-
niﬁcance of this ﬁnding is that patients with discordant visual
acuities may represent the patients with greatest potential reserve,
and therefore the patients that have the most clinical beneﬁt with
regard to preventing further visual loss.
Analysis of the different mitochondrial DNA mutations was con-
sistent with these ﬁndings. We saw the largest treatment effect
among patients harbouring the m.11778G4A and m.3460G4A
mutations. Among patients with the m.14484T4C mutation, the
genotype that has been reported to confer a better prognosis of
visual recovery, a high spontaneous recovery rate in the placebo
group was recorded, effectively abolishing a treatment effect in
these patients. It is important to note that there was no signiﬁcant
difference in the frequency of the m.14484T4C mutation be-
tween patients recruited with concordant and discordant visual
acuities. Thus, based on these 6-month study data, idebenone
appears to ameliorate the visual outcome particularly among pa-
tients with the m.11778G4A and m.3460G4A mutations, which
account for 80% of all European and North American cases with
LHON.
A key ﬁnding of this study was the minimal side-effect proﬁle
among patients with LHON treated with high-dose idebenone,
which was not different to placebo, and contributed to the
high compliance rates observed in this study. When combined
with other published data, this indicates that at 900mg/day, ide-
benone is safe and is well tolerated—a key factor in deciding
whether or not this new treatment should be used in clinical
practice.
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